Fennec Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $220.07 million
- Book Value:
- Revenue TTM:
- $3.21 million
- Operating Margin TTM:
- Gross Profit TTM:
- $1.45 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Fennec Pharmaceuticals Inc had its IPO on 2001-06-05 under the ticker symbol FENC.
The company operates in the Healthcare sector and Biotechnology industry. Fennec Pharmaceuticals Inc has a staff strength of 36 employees.
Shares of Fennec Pharmaceuticals Inc opened at $8.18 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.93 - $8.38, and closed at $8.04.
This is a -0.86% slip from the previous day's closing price.
A total volume of 70,048 shares were traded at the close of the day’s session.
In the last one week, shares of Fennec Pharmaceuticals Inc have slipped by -3.94%.
Fennec Pharmaceuticals Inc's Key Ratios
Fennec Pharmaceuticals Inc has a market cap of $220.07 million, indicating a price to book ratio of 92.3152 and a price to sales ratio of 829.8398.
In the last 12-months Fennec Pharmaceuticals Inc’s revenue was $3.21 million with a gross profit of $1.45 million and an EBITDA of $-13009000. The EBITDA ratio measures Fennec Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fennec Pharmaceuticals Inc’s operating margin was -756.94% while its return on assets stood at -74.18% with a return of equity of -1005.59%.
In Q1, Fennec Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Fennec Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fennec Pharmaceuticals Inc’s profitability.
Fennec Pharmaceuticals Inc stock is trading at a EV to sales ratio of 722.2629 and a EV to EBITDA ratio of -12.0398. Its price to sales ratio in the trailing 12-months stood at 829.8398.
Fennec Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.82 million
- Total Liabilities
- $4.02 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Fennec Pharmaceuticals Inc ended 2023 with $21.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.82 million while shareholder equity stood at $-7339000.00.
Fennec Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $4.02 million in other current liabilities, 142804000.00 in common stock, $-209252000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.39 million and cash and short-term investments were $18.39 million. The company’s total short-term debt was $0 while long-term debt stood at $24.66 million.
Fennec Pharmaceuticals Inc’s total current assets stands at $21.66 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.68 million compared to accounts payable of $2.95 million and inventory worth $918000.00.
In 2023, Fennec Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Fennec Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Fennec Pharmaceuticals Inc stock is currently trading at $8.04 per share. It touched a 52-week high of $10.85 and a 52-week low of $10.85. Analysts tracking the stock have a 12-month average target price of $16.33.
Its 50-day moving average was $8.3 and 200-day moving average was $8.8 The short ratio stood at 17.79 indicating a short percent outstanding of 0%.
Around 1728.1% of the company’s stock are held by insiders while 4785.6% are held by institutions.
Frequently Asked Questions About Fennec Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company’s product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.